UK markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.4000+0.0600 (+2.57%)
As of 12:31PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.3400
Bid2.3900 x 200
Ask2.4100 x 700
Day's range2.3100 - 2.4150
52-week range0.7000 - 3.4000
Avg. volume8,380,544
Market cap454.704M
Beta (5Y monthly)1.02
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Esperion to Participate in Upcoming BTIG Biotech Conference

    ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion TherapeuticsAt Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that i

  • GlobeNewswire

    New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

    – Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls – – Recent FDA-Approved Label Expansion For NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Allows Esperion the Opportunity to Help Educate the More Than 70 Million Americans Currently Dealing With High LDL-C In The U.S. – ANN ARBOR, Mich., July 16

  • GlobeNewswire

    Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

    – OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment – – Esperion Retains Rights to Receive all Potential Future Milestones of up to $300 Million Based on Commercial Performance from its Exclusive European Licensee, Daiichi Sankyo Europe – – Agreement Provides Increased Operational and Financial Flexibility and Strategically Leverages an Asset to Unenc